[ad_1]
S.Spíritus, Jul 15 (RHC) A new achievement of the Center for Genetic Engineering and Biotechnology (CIGB), is the suppository Proctokinase, a drug that validates its effectiveness in secondary health care for the treatment of acute hemorrhoidal seizures , According to Lázara Muñoz, CIGB specialist in Havana, the product was approved in January of the current year in the table of basic medicines and it is now prescribed by doctors in all countries . Cuba hospitals, which revolutionizes treatments for this disease, one of the most common proctologic conditions on the island.
The specialist pointed out to ACN that the latest research has indicated that out of 1555 patients, 62 percent had an early response to the fourth day of therapeutic treatment for acute hemorrhoidal crisis, and that in the six or seven days, the results were increased to a 97%.
Proctokinase is, until now, the only drug in the form of a suppository that has as active ingredient a biological product, in this case, it is the recombinant streptokinase, which has a fibrinolytic action, so that it acts directly in the affected area, said the Master in Biochemistry.
He said that these results are encouraging compared to those of other drugs manufactured, for example, in the United States – H Balm and Anusol HC – preparation, since Proctokinase He also noted that previously without this therapeutic treatment, the only solution was the surgery of choice, and that in this latest drug monitoring study, only 10 of these patients had
The researcher, one of those who intervened in the ICBB product development, pointed out that, according to Global Practices, in the specialty of Proctology, five percent of the population is suffering from hemorrhoids.
In Cuba, it is claimed that it is 2.5%, but proctologists say that it is a reserved number; therefore, it is thought that this disease behaves in the country very similar at the global level, he said.
He said that until now the suppository must be prescribed by a specialist, because any hemorrhagic event can be confusing and, therefore, the doctor must confirm that the patient is facing an acute hemorrhoidal crisis.
Its use has not yet been proven for pregnant or puerperal women, although we are preparing a protocol for these cases, and should not be applied in those recently operated, after streptococcal infection or in people having problems with coagulation, he details.
Recombinant streptokinase is a thrombolytic also used in cardiac infarctions.
Some of the benefits that are obtained during the application of the drugs are related to the reduction of a short period of inflammation and pain, in addition to the elimination of clots formed in the bad region of the patient.
Source link
